(-0.09%) 5 142.50 points
(-0.04%) 38 542 points
(-0.03%) 17 900 points
(-0.23%) $82.44
(1.23%) $2.06
(-1.03%) $2 333.40
(-2.39%) $27.00
(-0.67%) $955.10
(0.30%) $0.935
(0.53%) $11.04
(0.28%) $0.798
(-0.25%) $93.06
Live Chart Being Loaded With Signals
Kissei Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products primarily in Japan. It offers Urief and Urief OD tablets for the treatment of dysuria; Glufast, Glubes, and Marizev tablets for type 2 diabetes; Darbepoetin Alfa BS and Epoetin Alfa BS injections for the treatment of renal anemia; Beova tablets for overactive bladder treatment; P-TOL chewable tablets for treating hyperphosphatemia; and Minirin Melt OD tablets for nocturia due to nocturnal polyuria in males, central diabetes insipidus, and nocturnal enuresis resulted from decrease of urine osmolality...
Stats | |
---|---|
आज की मात्रा | 47 400.00 |
औसत मात्रा | 92 366.00 |
बाजार मूल्य | 161.14B |
EPS | ¥0 ( 2024-01-30 ) |
अगली कमाई की तारीख | ( ¥110.76 ) 2024-05-06 |
Last Dividend | ¥40.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 13.59 |
ATR14 | ¥3.42 (0.09%) |
मात्रा सहसंबंध
Kissei Pharmaceutical सहसंबंध
10 सबसे अधिक सकारात्मक सहसंबंध |
---|
10 सबसे अधिक नकारात्मक सहसंबंध |
---|
क्या आप जानते हैं?
कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।
कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।
Kissei Pharmaceutical सहसंबंध - मुद्रा/वस्त्र
Kissei Pharmaceutical वित्तीय
Annual | 2022 |
राजस्व: | ¥67.49B |
सकल लाभ: | ¥32.38B (47.97 %) |
EPS: | ¥228.30 |
FY | 2022 |
राजस्व: | ¥67.49B |
सकल लाभ: | ¥32.38B (47.97 %) |
EPS: | ¥228.30 |
FY | 2022 |
राजस्व: | ¥65.38B |
सकल लाभ: | ¥31.24B (47.78 %) |
EPS: | ¥280.20 |
FY | 2021 |
राजस्व: | ¥69.04B |
सकल लाभ: | ¥32.72B (47.39 %) |
EPS: | ¥113.25 |
Financial Reports:
No articles found.
Kissei Pharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥40.00 (N/A) |
¥0 (N/A) |
¥40.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥7.00 | 2001-03-27 |
Last Dividend | ¥40.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 46 | -- |
Total Paid Out | ¥794.00 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.68 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.36 | |
Div. Directional Score | 7.40 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8537.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7860.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7003.T | Ex Dividend Junior | 2024-03-28 | Sporadic | 0 | 0.00% | |
6356.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
5210.T | Ex Dividend Knight | 2024-03-28 | Annually | 0 | 0.00% | |
4318.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
3482.T | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% | |
2695.T | Ex Dividend Junior | 2023-10-30 | Annually | 0 | 0.00% | |
9605.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
8151.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.165 | 1.500 | 6.69 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0534 | 1.200 | 8.22 | 9.86 | [0 - 0.3] |
returnOnEquityTTM | 0.0620 | 1.500 | -0.422 | -0.634 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 5.93 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 4.22 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 1.155 | 1.500 | 4.69 | 7.04 | [0.2 - 2] |
debtRatioTTM | 0.00608 | -1.500 | 9.90 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 141.28 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 186.97 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 186.97 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.00707 | -1.500 | 9.97 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.482 | 1.000 | 5.29 | 5.29 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0345 | 1.000 | -1.310 | -1.310 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 6.04 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.323 | 0.800 | -1.182 | -0.946 | [0.5 - 2] |
Total Score | 10.43 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 13.21 | 1.000 | 8.77 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0620 | 2.50 | -0.272 | -0.634 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 186.97 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.29 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 186.97 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.0896 | 1.500 | -2.74 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.114 | 1.000 | 9.65 | 0 | [0.1 - 0.5] |
Total Score | 4.36 |
Kissei Pharmaceutical
Kissei Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products primarily in Japan. It offers Urief and Urief OD tablets for the treatment of dysuria; Glufast, Glubes, and Marizev tablets for type 2 diabetes; Darbepoetin Alfa BS and Epoetin Alfa BS injections for the treatment of renal anemia; Beova tablets for overactive bladder treatment; P-TOL chewable tablets for treating hyperphosphatemia; and Minirin Melt OD tablets for nocturia due to nocturnal polyuria in males, central diabetes insipidus, and nocturnal enuresis resulted from decrease of urine osmolality. The company's products in pipeline include KPS-0373 that has completed Phase III clinical trial to treat spinocerebellar ataxia; CCX168, which has completed Phase III clinical trial for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis; AJM300, which is in Phase III clinical trial to treat ulcerative colitis; R788 that is in Phase III clinical trial to treat chronic idiopathic thrombocytopenic purpura; and MR13A9, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients. It is also developing KLH-2109 for treating endometriosis and uterine fibroids; KDT-3594 for the treatment of Parkinson's disease; Silodosin for dysuria associated with benign prostatic hyperplasia; Mitiglinide for type 2 diabetes mellitus; and Bedoradrine for the treatment of acute exacerbation of asthma. In addition, it develops and sells protein controlled and energy supply foods; and purchases and sells related materials, as well as offers system development and information processing, construction contracting, equipment and facility management, and information gathering and development support services. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. The company was founded in 1946 and is headquartered in Matsumoto, Japan.
के बारे में लाइव सिग्नल्स
इस पृष्ठ पर प्रस्तुत लाइव सिग्नल्स NA को कब खरीदना या बेचना है, इसका निर्धारण करने में मदद करते हैं। सिग्नल्स में 1-मिनट की देरी हो सकती है; सभी बाजार सिग्नल्स की तरह, त्रुटि या गलतियों की संभावना होती है।
लाइव ट्रेडिंग सिग्नल्स स्थायी नहीं हैं, और getagraph.com इन सिग्नल्स पर किए गए किसी भी कार्रवाई के लिए जिम्मेदारी नहीं रखते हैं, जैसा कि उपयोग की शर्तें में वर्णित है। सिग्नल्स एक व्यापक श्रृंखला के तकनीकी विश्लेषण संकेतकों पर आधारित हैं